(Q43027727)

English

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

scientific article published on 9 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

methylprednisolone

1 reference

based on heuristic

inferred from title

Cris Constantinescu

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Per Soelberg Sørensen

2

object named as

Per Soelberg Sørensen

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

object named as

Ellen Garde

10

0 references

Elisabeth Gulowsen Celius

4

object named as

Elisabeth G Celius

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Mads Ravnborg

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Magnus Andersson

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peter J Jongen

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Irina Elovaara

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Emmanuel Bartholomé

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Karsten Beer

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bjørn Sperling

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

9 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

672-680

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

USE OF AN ORAL CORTICOSTEROID IN THE TREATMENT OF MULTIPLE SCLEROSIS; A DOUBLE-BLIND STUDY

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970132-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(10)70132-0

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

release_nuozl3istzgrvcr4w4r3ux4b6q

1 reference

https://api.fatcat.wiki/v0/release/nuozl3istzgrvcr4w4r3ux4b6q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43027727&oldid=1977603911"